sitagliptin
Trade name: januvia
Small moleculeapproved
Approved
Oct 16, 2006
Sitagliptin (MK-0431), chemically (2R)-4-Oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifl uorophenyl)butan-2-amine has a very high selectivity towards DPP-4, with an IC(50) of 18 nM. There is no affinity towards other DDP enzymes (DPP- 8 and DPP-9). It has been approved for the treatment of type 2 diabetes in the USA and Europe and is registered by the name Januvia (Merck Pharmaceuticals, Whitehouse Station, NJ, USA). In healthy volunteers and in patients with type 2 diabetes of different ethnic background, the tolerability of different doses given once or twice daily is good. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin. Sitagliptin is an incretin enhancer and the first marketed medication belonging to the gliptin class. In fact, no published literature exists regarding incidence or severity of hypoglycemia when sitagliptin is used off-label in combined with insulin therapy. However, is recommended to use methods to avoid hypoglycemia when using this off-label combination. Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination. Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin — NCATS
Clinical trial activity
1,778 trials · 840 clinical orgs · 30 marketing orgs
Phase 1
381
Phase 2
726
Phase 3
452
Phase 4
439
Earliest trial started Dec 1, 1997 (NCT00413179)
Timeline
1990s
- Jan 1, 1997
Earliest Phase 3 Sponsor(trial)
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
- May 25, 1999
SmithKline Beecham — NDA Secondary Org
2000s
- Oct 16, 2006
Merck — Earliest FDA Approval
- Oct 16, 2006
Merck — NDA Organization
- Oct 16, 2006
Merck — NDA Secondary Org
- Oct 16, 2006
Merck — Marketing Organization
- Jan 31, 2007
Watson Pharmaceuticals — Marketing Organization
- Mar 10, 2008
Roxane Laboratories — Marketing Organization
- Dec 2, 2008
Mylan — Marketing Organization
- Mar 9, 2009
Sandoz — Marketing Organization
- Dec 8, 2009
Hikma — Marketing Organization
2010s
- Jan 25, 2013
Ani Pharmaceuticals — Marketing Organization
- Jan 25, 2013
Teva — Marketing Organization
- Apr 11, 2013
Sun Pharmaceuticals — Marketing Organization
- Jul 30, 2013
Novartis — Marketing Organization
- Feb 18, 2014
Apotex — Marketing Organization
- Apr 15, 2014
Actavis — Marketing Organization
- Apr 21, 2015
Anchen Pharmaceuticals, Inc — Marketing Organization
- Apr 21, 2015
Par Pharmaceuticals — Marketing Organization
- Oct 30, 2015
Allergan PLC (2015) — Marketing Organization
- Apr 29, 2016
Dr. Reddy's Laboratories — Marketing Organization
- Jul 3, 2017
Zydus Discovery DMCC — Marketing Organization
2020s
- Jan 5, 2021
Ajanta Pharma Ltd — Marketing Organization
- Jul 9, 2021
Unichem — Marketing Organization
- Sep 2, 2021
Zydus Discovery DMCC — NDA Secondary Org
- Apr 8, 2022
Alkem Labs Ltd — Marketing Organization
- Jan 2, 2024
Mankind Pharma — Marketing Organization
- Jan 16, 2025
Azurity — Marketing Organization
- Mar 6, 2025
Sciegen Pharmaceticals — Marketing Organization
- Apr 2, 2025
Macleods Pharmaceuticals, Ltd — Marketing Organization
- Jun 4, 2025
PH HEALTH — Marketing Organization
- Jul 23, 2025
MSN Laboratories — Marketing Organization
- Aug 25, 2025
Biocon Limited — Marketing Organization
- Nov 12, 2025
Laurus Labs Ltd — Marketing Organization
- Jan 26, 2026
Fosun — Marketing Organization
Indications
Studied for
- Abortion, Habitual · Phase 4
- Abortion, Spontaneous · Phase 3
- Acanthosis Nigricans · Phase 4
- Acromegaly · Phase 4
- Acute Coronary Syndrome · Phase 4
- Acute-On-Chronic Liver Failure · Phase 4
- Adenocarcinoma · Phase 2
- Adenocarcinoma, Bronchiolo-Alveolar · Phase 2
- Adenocarcinoma of Lung · Phase 2
- Adenomatous Polyposis Coli · Phase 2
- Adenomatous Polyps · Phase 2
- Aging · Phase 4
- Albuminuria · Phase 4
- Altitude Sickness · Phase 4
- Alzheimer Disease · Phase 3
- Amenorrhea · Phase 4
- Anemia · Phase 1
- Anemia, Sickle Cell · Early Phase 1
- Angina Pectoris · Phase 4
- Angina, Unstable · Phase 4
- Anovulation · Phase 4
- Anxiety Disorders · Phase 1
- Art · Phase 1/Phase 2
- Arteriosclerosis · Phase 4
- Arthritis, Rheumatoid · Phase 2
- Ascites · Phase 2
- Asthma · Phase 2/Phase 3
- Ataxia Telangiectasia · Phase 4
- Atherosclerosis · Phase 4
- Atrial Fibrillation · Phase 4
- Auditory Diseases, Central · Phase 4
- Autism Spectrum Disorder · Phase 4
- Autoimmune Diseases · Phase 1
- Barrett Esophagus · Phase 2
- beta-Thalassemia · Phase 4
- Bipolar Disorder · Phase 4
- Blood Coagulation Disorders · Phase 2
- Blood Glucose · Phase 4
- Blood Platelet Disorders · Phase 2/Phase 3
- Body Weight · Phase 4
- Body Weight Changes · Phase 1/Phase 2
- Bone Diseases · Phase 2
- Bone Marrow Cells · Phase 2
- Bone Marrow Transplantation · Phase 1/Phase 2
- Brain Neoplasms · Phase 3
- BRCA1 Protein · Phase 3
- Breast Diseases · Phase 4
- Breast Neoplasms · Phase 3
- Brenner Tumor · Phase 2
- Burns · Phase 2/Phase 3
- Carcinoma · Phase 2
- Carcinoma, Adenosquamous · Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Mucoepidermoid · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Cardiovascular Diseases · Phase 4
- Cholangiocarcinoma · Phase 1/Phase 2
- Cholestasis, Intrahepatic · Phase 2/Phase 3
- Cholesterol, LDL · Phase 4
- Chondrosarcoma · Phase 1/Phase 2
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 3
- Chronic Periodontitis · Phase 2/Phase 3
- Cognitive Dysfunction · Phase 4
- Colitis, Ulcerative · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 3
- Coronary Artery Bypass · Phase 3
- Coronary Artery Disease · Phase 4
- Coronary Disease · Phase 4
- Coronary Restenosis · Phase 4
- COVID-19 · Phase 3
- Critical Illness · Phase 3
- Cushing Syndrome · Phase 2/Phase 3
- Cystic Fibrosis · Phase 3
- Dementia · Phase 2
- Dementia, Vascular · Phase 2
- Depression · Phase 4
- Diabetes, Gestational · Phase 4
- Diabetes Insipidus · Phase 1
- Diabetes Mellitus, Type 1 · Phase 4
- Diabetic Foot · Phase 3
- Diabetic Nephropathies · Phase 3
- Diabetic Neuropathies · Phase 3
- Diabetic Retinopathy · Early Phase 1
- Diet · Early Phase 1
- Dipeptidyl-Peptidase IV Inhibitors · Phase 4
- Drug Interactions · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drugs, Generic · Phase 1
- Drugs, Investigational · Phase 3
- Drug Therapy · Phase 4
- Dyslipidemias · Phase 4
- Endocrine System Diseases · Phase 2
- Endometrial Hyperplasia · Phase 2
- Endometrial Neoplasms · Phase 4
- Endometriosis · Phase 2/Phase 3
- Endothelial Cells · Phase 4
- Endothelium · Phase 4
- Epidermal Growth Factor · Phase 2
- Erectile Dysfunction · Phase 1
- Erythrocytes, Abnormal · Phase 2
- Esophageal Neoplasms · Phase 2
- Exercise · Phase 4
- Fallopian Tube Neoplasms · Phase 2
- Fasting · Phase 1
- Fatty Liver · Phase 4
- Fibromyalgia · Phase 2
- Fibrosis · Phase 3
- Frail Elderly · Phase 3
- Frailty · Phase 2
- Gastroparesis · Phase 2
- General Surgery · Phase 4
- Genetic Diseases, Inborn · Phase 4
- Geographic Atrophy · Phase 2
- Glioblastoma · Phase 2
- Glioma · Phase 1/Phase 2
- Gliosarcoma · Phase 1
- Glomerulosclerosis, Focal Segmental · Phase 1
- Glucocorticoids · Phase 4
- Glucose Intolerance · Phase 4
- Glucose Metabolism Disorders · Phase 4
- Glycated Hemoglobin · Phase 4
- Glycemic Control · Phase 3
- Gonadal Disorders · Phase 4
- Graft vs Host Disease · Phase 3
- Gynecology · Phase 3
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 2
- Healthy Volunteers · Phase 4
- Hearing Loss, Sensorineural · Phase 2/Phase 3
- Heart Diseases · Phase 3
- Heart Failure · Phase 4
- Heart Failure, Diastolic · Phase 2
- Heart Failure, Systolic · Phase 4
- Heart Ventricles · Phase 4
- Hemangiosarcoma · Phase 2
- Hematopoietic Stem Cell Transplantation · Phase 3
- Hemoglobins · Early Phase 1
- Hepatic Encephalopathy · Phase 4
- Hepatic Insufficiency · Phase 1
- Hepatitis · Phase 2
- Hepatitis C · Phase 4
- Hepatitis C, Chronic · Phase 4
- HIV · Phase 2
- HIV-Associated Lipodystrophy Syndrome · Phase 2
- HIV Infections · Phase 4
- Hospitalization · Phase 4
- Hyperandrogenism · Phase 3
- Hypercholesterolemia · Phase 3
- Hyperglycemia · Phase 4
- Hyperinsulinism · Phase 4
- Hyperlactatemia · Phase 1/Phase 2
- Hyperlipidemias · Phase 3
- Hyperplasia · Phase 3
- Hypertension · Phase 4
- Hypertriglyceridemia · Phase 4
- Hypertrophy, Left Ventricular · Phase 4
- Hypoglycemia · Phase 4
- Hypoglycemic Agents · Phase 4
- Hypogonadism · Phase 3
- Infertility · Phase 4
- Infertility, Female · Phase 3
- Inflammation · Phase 4
- Inflammatory Bowel Diseases · Phase 4
- Insulin Resistance · Phase 4
- Insulin Secretion · Phase 4
- Intermittent Claudication · Phase 4
- Iron Metabolism Disorders · Phase 2/Phase 3
- Islets of Langerhans Transplantation · Phase 3
- Ketosis · Phase 4
- Kidney Failure, Chronic · Phase 4
- Kidney Neoplasms · Phase 2
- Kidney Transplantation · Phase 2
- Lactation Disorders · Phase 1/Phase 2
- Larynx · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Monocytic, Acute · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Leukemia, Myelomonocytic, Acute · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1/Phase 2
- Leukoplakia, Oral · Phase 2
- Lewy Body Disease · Phase 4
- Li-Fraumeni Syndrome · Phase 1
- Lip · Phase 2
- Lipodystrophy · Phase 4
- Lipoproteins · Phase 3
- Liver Cirrhosis · Phase 4
- Liver Diseases · Phase 4
- Liver Neoplasms · Phase 3
- Liver Transplantation · Phase 4
- Lung Neoplasms · Phase 2
- Lupus Erythematosus, Systemic · Phase 4
- Lymphoma · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, T-Cell, Cutaneous · Phase 2
- Macrophages · Phase 3
- Macular Degeneration · Phase 2
- Malaria · Phase 1
- Malaria, Falciparum · Phase 1/Phase 2
- Masked Hypertension · Phase 4
- Melanoma · Phase 2
- Memory Disorders · Phase 2
- Menopause · Phase 4
- Metabolic Diseases · Phase 4
- Metabolic Syndrome · Phase 4
- Metabolism · Phase 2/Phase 3
- Metformin · Phase 4
- Migraine Disorders · Phase 3
- Mitochondrial Diseases · Phase 2
- Mouth · Phase 2
- Movement Disorders · Phase 2
- Multiple Myeloma · Phase 2
- Multiple Organ Failure · Phase 3
- Muscular Dystrophies · Phase 2
- Muscular Dystrophy, Duchenne · Phase 3
- Mutation · Phase 3
- Mycosis Fungoides · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myocardial Infarction · Phase 4
- Myocardial Ischemia · Phase 4
- Myoma · Phase 1/Phase 2
- Neoplasms · Phase 4
- Neoplasms, Adipose Tissue · Phase 4
- Neuralgia · Phase 1
- Neuroendocrine Tumors · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 4
- Nutritional and Metabolic Diseases · Phase 2
- Obesity · Phase 4
- Obesity, Abdominal · Phase 4
- Optic Atrophy · Phase 2/Phase 3
- Organic Cation Transporter 2 · Phase 4
- Oropharyngeal Neoplasms · Phase 2
- Osteoporosis · Phase 3
- Osteoporosis, Postmenopausal · Phase 3
- Ovarian Neoplasms · Phase 2
- Overweight · Phase 4
- Ovulation · Phase 3
- Oxidative Stress · Phase 2
- Pancreatic Neoplasms · Phase 4
- Pancreatitis · Phase 4
- Parkinson Disease · Phase 4
- Patients · Phase 1
- Pediatric Obesity · Phase 4
- Peptic Ulcer · Phase 2/Phase 3
- Percutaneous Coronary Intervention · Phase 4
- Periodontitis · Phase 2/Phase 3
- Peripheral Arterial Disease · Phase 4
- Pharmacokinetics · Phase 1
- Pharmacological and Toxicological Phenomena · Phase 3
- Pharmacology · Phase 4
- Pharynx · Phase 2
- Physiological Effects of Drugs · Phase 2
- Pituitary ACTH Hypersecretion · Phase 4
- Pleural Effusion, Malignant · Phase 2
- Polycystic Kidney, Autosomal Dominant · Phase 2
- Polycystic Ovary Syndrome · Phase 4
- Polymorphism, Genetic · Phase 4
- Postmenopause · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Prediabetic State · Phase 4
- Pregnancy · Phase 4
- Pregnancy Complications · Phase 2/Phase 3
- Pregnancy in Diabetics · Phase 4
- Prognosis · Phase 4
- Prostatic Neoplasms · Phase 4
- Psoriasis · Phase 3
- Psychotic Disorders · Phase 4
- Pulmonary Arterial Hypertension · Phase 2
- Pulmonary Disease, Chronic Obstructive · Phase 4
- Purpura, Thrombocytopenic, Idiopathic · Phase 2
- Quality of Life · Phase 4
- Rectal Neoplasms · Phase 2
- Renal Dialysis · Phase 1
- Renal Insufficiency · Phase 3
- Renal Insufficiency, Chronic · Phase 3
- Reperfusion Injury · Phase 4
- Reproductive Health · Phase 2
- Safety · Phase 2
- Sarcoma · Phase 2
- Schizophrenia · Phase 4
- Sezary Syndrome · Phase 2
- Short Bowel Syndrome · Phase 4
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Therapeutic Equivalency · Phase 1
- Therapeutics · Phase 2
- Thrombocytopenia · Phase 2
- Thyroid Cancer, Papillary · Phase 1
- Thyroid Neoplasms · Phase 1
- Toxemia · Phase 3
- Tryptophan · Early Phase 1
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Uterine Neoplasms · Phase 2/Phase 3
- Vascular Diseases · Phase 4
- Weight Gain · Phase 4
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Combination products
janumet
with metformin
Also known as janumet xr
juvisync
with simvastatin
steglujan
with ertugliflozin
Approval history
- approvedOct 16, 2006
Chemistry & pharmacology
Loading structure…
SMILES
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F- Mol. weight
- 407.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1422 ↗
- WikipediaSitagliptin ↗
- NCATSQFP0P1DV7Z ↗
- ChEMBLCHEMBL1201174 ↗
Also known as
- 1,1-dimethylbiguanide
- 1,1-dimethylbiguanide
- 1,1-dimethylbiguanide
- 2,4-thiazolidinedione, 5-004-02-((((methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-
- (2r)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
- (2r)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine
- 5-((4-(2-methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate
- (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
- (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
- dimethylbiguanid
- dimethylbiguanid
- dimethyldiguanide
- dimethyldiguanide
- ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate
- glaxosmithkline brand of rosiglitazone maleate
- glaxo wellcome brand of rosiglitazone maleate
- januvia
- januvia
- januvia
- januvia
- mk0431
- mk0431
- mk 0431
- mk-0431
- mk-0431
- mk-0431
- mk-0431
- mk-0431
- n,n-dimethylguanylguanidine
- ono-5435
- ono-5435
- ristaben
- (rs)-5-{4-[2-(methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion
- (rs)-5-{4-[2-(methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion
- sitagliptan
- sitagliptan
- sitagliptin
- sitagliptin
- sitagliptin
- sitagliptin
- sitagliptin
- sitagliptin
- sitagliptin
- sitagliptin
- sitagliptin
- sitagliptin
- sitagliptin
- sitagliptina
- sitagliptina
- sitagliptine
- sitagliptine
- sitagliptin / metformin hydrochloride
- sitagliptin monophosphate monohydrate
- sitagliptin phosphate
- sitagliptin phosphate
- sitagliptin phosphate
- sitagliptin phosphate
- sitagliptin phosphate
- sitagliptin phosphate
- sitagliptin phosphate anhydrous
- sitagliptin phosphate hydrate
- sitagliptin phosphate monohydrate
- sitagliptinum
- sitagliptinum
- smithkline beecham brand of rosiglitazone maleate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06560333 | Phase 3 | Nov 30, 2026 | Eurofarma Laboratorios S.A. |
| NCT07241897 | Phase 3 | Dec 15, 2025 | Soochow University |
| NCT07003542 | Phase 2 | Aug 8, 2025 | Case Western Reserve University |
| NCT07073768 | Phase 3 | Jul 1, 2025 | Khyber Medical University Peshawar, Khyber Medical University Peshawer |
| NCT06972732 | Phase 4 | Jun 11, 2025 | Boryung Pharmaceutical Company |
| NCT06851962 | Phase 4 | Apr 30, 2025 | University of Valencia |
| NCT06759922 | Phase 4 | Jan 1, 2025 | Bahria University |
| NCT06246799 | Phase 3 | Nov 30, 2024 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Texas, San Antonio |
| NCT07083232 | Phase 4 | Oct 30, 2024 | Al Azhar University |
| NCT07172269 | N/A | Sep 15, 2024 | Al-Mustansiriyah University |
| NCT06587698 | N/A | Aug 21, 2024 | Peking University |
| NCT06233201 | Phase 1 | Jun 4, 2024 | Bio-innova Co., Ltd |
| NCT06613750 | Phase 4 | Jun 1, 2024 | Guangzhou Medical University, Southern Medical University |
| NCT06952231 | Phase 3 | May 21, 2024 | University of Health Sciences Lahore |
| NCT06263673 | Phase 4 | May 7, 2024 | Mayo Clinic |
| NCT06233240 | Phase 1 | Apr 30, 2024 | Bio-innova Co., Ltd |
| NCT06329882 | Phase 1/Phase 2 (Phase 2) | Mar 30, 2024 | Tanta University |
| NCT05833958 | Phase 2 | Jan 31, 2024 | George Medicines PTY Limited, University of New South Wales |
| NCT06187285 | N/A | Jan 1, 2024 | Diabetes & Endocrinology Foundation, Medanta - The Medicity |
| NCT06164535 | Phase 4 | Dec 30, 2023 | Beni Suef University, Minia University |
Showing 20 of 1,778 trials
Page 1 / 89
Organizations
Research & Development (840)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 159 | 110 | 5 | 1998 |
| GlaxoSmithKline | For profit | 97 | 66 | 5 | 2000 |
| AstraZeneca | For profit | 84 | 74 | 5 | 2004 |
| Novo Nordisk | For profit | 71 | 57 | 5 | 1998 |
| Sanofi | For profit | 63 | 58 | 4 | 2001 |
| Bristol-Myers Squibb | For profit | 57 | 8 | 4 | 2001 |
| Boehringer Ingelheim | For profit | 52 | 52 | 4 | 2005 |
| Eli Lilly | For profit | 48 | 13 | 5 | 2000 |
| Johnson and Johnson | For profit | 40 | 38 | 5 | 2007 |
| National Cancer Institute (NCI) | Government | 36 | 9 | 4 | 1999 |
| Novartis | For profit | 35 | 31 | 4 | 2004 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 29 | 8 | 5 | 1999 |
| Takeda | For profit | 29 | 24 | 5 | 1998 |
| Seoul National University | Academic/Hospital | 27 | 18 | 5 | 2008 |
| University of Toronto | Academic/Hospital | 24 | 18 | 4 | 2003 |
| Harvard University | Academic/Hospital | 23 | 18 | 5 | 1999 |
| National Institutes of Health (NIH) | Government | 23 | 7 | 5 | 2000 |
| University of Copenhagen | Academic/Hospital | 20 | 17 | 5 | 2004 |
| People's Liberation Army of China | Government | 18 | 13 | 4 | 2007 |
| Pfizer | For profit | 17 | 7 | 4 | 2001 |
840 organizations
Page 1 / 42
Marketing (44)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Actavis | For profit | MKTG | Apr 15, 2014 |
| Ajanta Pharma Ltd | For profit | MKTG | Jan 5, 2021 |
| Alkem Labs Ltd | For profit | MKTG | Apr 8, 2022 |
| Allergan PLC (2015) | For profit | MKTG | Oct 30, 2015 |
| Anchen Pharmaceuticals, Inc | For profit | MKTG | Apr 21, 2015 |
| Ani Pharmaceuticals | For profit | MKTG | Jan 25, 2013 |
| Apotex | For profit | MKTG | Feb 18, 2014 |
| Apotex | For profit | SYN | Jan 20, 2026 |
| Azurity | For profit | MKTG | Jan 16, 2025 |
| Biocon Limited | For profit | MKTG | Aug 25, 2025 |
| Dr. Reddy's Laboratories | For profit | MKTG | Apr 29, 2016 |
| Dr. Reddy's Laboratories | For profit | SYN | May 12, 2025 |
| Fosun | For profit | MKTG | Jan 26, 2026 |
| Hikma | For profit | MKTG | Dec 8, 2009 |
| Laurus Labs Ltd | For profit | MKTG | Nov 12, 2025 |
| MSN Laboratories | For profit | MKTG | Jul 23, 2025 |
| Macleods Pharmaceuticals, Ltd | For profit | MKTG | Apr 2, 2025 |
| Mankind Pharma | For profit | MKTG | Jan 2, 2024 |
| Merck | For profit | NDA | Oct 16, 2006 |
| Merck | For profit | NDA2 | Oct 16, 2006 |
| Merck | For profit | SYN | Mar 30, 2007 |
| Merck | For profit | MKTG | Oct 16, 2006 |
| Mylan | For profit | MKTG | Dec 2, 2008 |
| Mylan | For profit | SYN | Oct 10, 2012 |
| Novartis | For profit | MKTG | Jul 30, 2013 |
| PH HEALTH | For profit | MKTG | Jun 4, 2025 |
| Par Pharmaceuticals | For profit | MKTG | Apr 21, 2015 |
| Roxane Laboratories | For profit | MKTG | Mar 10, 2008 |
| Sandoz | For profit | MKTG | Mar 9, 2009 |
| Sandoz | For profit | SYN | Jan 30, 2013 |
| Sciegen Pharmaceticals | For profit | MKTG | Mar 6, 2025 |
| SmithKline Beecham | For profit | NDA2 | May 25, 1999 |
| Sun Pharmaceuticals | For profit | MKTG | Apr 11, 2013 |
| Teva | For profit | MKTG | Jan 25, 2013 |
| Teva | For profit | SYN | Feb 23, 2015 |
| Teva | For profit | SYN | Sep 29, 2015 |
| Unichem | For profit | MKTG | Jul 9, 2021 |
| Watson Pharmaceuticals | For profit | MKTG | Jan 31, 2007 |
| Watson Pharmaceuticals | For profit | SYN | Apr 15, 2014 |
| Zydus Discovery DMCC | For profit | SYN | Oct 18, 2023 |
| Zydus Discovery DMCC | For profit | MKTG | Jul 3, 2017 |
| Zydus Discovery DMCC | For profit | MKTG | Sep 2, 2021 |
| Zydus Discovery DMCC | For profit | NDA2 | Sep 2, 2021 |
| Zydus Discovery DMCC | For profit | SYN | Oct 18, 2023 |